Development of a rat plasma and brain extracellular fluid pharmacokinetic model for bupropion and hydroxybupropion based on microdialysis sampling, and application to predict human brain concentrations

Thomas I.F.H. Cremers, Gunnar Flik, Joost H.A. Folgering, Hans Rollema, Robert Stratford Jr.

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Administration of bupropion [(6)-2-(tert-butylamino)-1-(3-chlorophenyl) propan-1-one] and its preformed active metabolite, hydroxybupropion [(6)-1-(3-chlorophenyl)-2-[(1-hydroxy-2-methyl-2-propanyl)amino]- 1-propanone], to rats with measurement of unbound concentrations by quantitative microdialysis sampling of plasma and brain extracellular fluid was used to develop a compartmental pharmacokinetics model to describe the blood-brain barrier transport of both substances. The population model revealed rapid equilibration of both entities across the blood-brain barrier, with resultant steadystate brain extracellular fluid/plasma unbound concentration ratio estimates of 1.9 and 1.7 for bupropion and hydroxybupropion, respectively, which is thus indicative of a net uptake asymmetry. An overshoot of the brain extracellular fluid/plasma unbound concentration ratio at early time points was observed with bupropion; this was modeled as a time-dependent uptake clearance of the drug across the blood-brain barrier. Translation of the model was used to predict bupropion and hydroxybupropion exposure in human brain extracellular fluid after twice-daily administration of 150 mg bupropion. Predicted concentrations indicate that preferential inhibition of the dopamine and norepinephrine transporters by the metabolite, with little to no contribution by bupropion, would be expected at this therapeutic dose. Therefore, these results extend nuclear imaging studies on dopamine transporter occupancy and suggest that inhibition of both transporters contributes significantly to bupropion's therapeutic efficacy.

Original languageEnglish (US)
Pages (from-to)624-633
Number of pages10
JournalDrug Metabolism and Disposition
Volume44
Issue number5
DOIs
StatePublished - May 1 2016
Externally publishedYes

Fingerprint

Bupropion
Extracellular Fluid
Microdialysis
Pharmacokinetics
Brain
Blood-Brain Barrier
Dopamine Plasma Membrane Transport Proteins
Norepinephrine Plasma Membrane Transport Proteins
hydroxybupropion
Therapeutics
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Development of a rat plasma and brain extracellular fluid pharmacokinetic model for bupropion and hydroxybupropion based on microdialysis sampling, and application to predict human brain concentrations. / Cremers, Thomas I.F.H.; Flik, Gunnar; Folgering, Joost H.A.; Rollema, Hans; Stratford Jr., Robert.

In: Drug Metabolism and Disposition, Vol. 44, No. 5, 01.05.2016, p. 624-633.

Research output: Contribution to journalArticle

@article{2861c92c77a4445b95d62c14ae266ed0,
title = "Development of a rat plasma and brain extracellular fluid pharmacokinetic model for bupropion and hydroxybupropion based on microdialysis sampling, and application to predict human brain concentrations",
abstract = "Administration of bupropion [(6)-2-(tert-butylamino)-1-(3-chlorophenyl) propan-1-one] and its preformed active metabolite, hydroxybupropion [(6)-1-(3-chlorophenyl)-2-[(1-hydroxy-2-methyl-2-propanyl)amino]- 1-propanone], to rats with measurement of unbound concentrations by quantitative microdialysis sampling of plasma and brain extracellular fluid was used to develop a compartmental pharmacokinetics model to describe the blood-brain barrier transport of both substances. The population model revealed rapid equilibration of both entities across the blood-brain barrier, with resultant steadystate brain extracellular fluid/plasma unbound concentration ratio estimates of 1.9 and 1.7 for bupropion and hydroxybupropion, respectively, which is thus indicative of a net uptake asymmetry. An overshoot of the brain extracellular fluid/plasma unbound concentration ratio at early time points was observed with bupropion; this was modeled as a time-dependent uptake clearance of the drug across the blood-brain barrier. Translation of the model was used to predict bupropion and hydroxybupropion exposure in human brain extracellular fluid after twice-daily administration of 150 mg bupropion. Predicted concentrations indicate that preferential inhibition of the dopamine and norepinephrine transporters by the metabolite, with little to no contribution by bupropion, would be expected at this therapeutic dose. Therefore, these results extend nuclear imaging studies on dopamine transporter occupancy and suggest that inhibition of both transporters contributes significantly to bupropion's therapeutic efficacy.",
author = "Cremers, {Thomas I.F.H.} and Gunnar Flik and Folgering, {Joost H.A.} and Hans Rollema and {Stratford Jr.}, Robert",
year = "2016",
month = "5",
day = "1",
doi = "10.1124/dmd.115.068932",
language = "English (US)",
volume = "44",
pages = "624--633",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

TY - JOUR

T1 - Development of a rat plasma and brain extracellular fluid pharmacokinetic model for bupropion and hydroxybupropion based on microdialysis sampling, and application to predict human brain concentrations

AU - Cremers, Thomas I.F.H.

AU - Flik, Gunnar

AU - Folgering, Joost H.A.

AU - Rollema, Hans

AU - Stratford Jr., Robert

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Administration of bupropion [(6)-2-(tert-butylamino)-1-(3-chlorophenyl) propan-1-one] and its preformed active metabolite, hydroxybupropion [(6)-1-(3-chlorophenyl)-2-[(1-hydroxy-2-methyl-2-propanyl)amino]- 1-propanone], to rats with measurement of unbound concentrations by quantitative microdialysis sampling of plasma and brain extracellular fluid was used to develop a compartmental pharmacokinetics model to describe the blood-brain barrier transport of both substances. The population model revealed rapid equilibration of both entities across the blood-brain barrier, with resultant steadystate brain extracellular fluid/plasma unbound concentration ratio estimates of 1.9 and 1.7 for bupropion and hydroxybupropion, respectively, which is thus indicative of a net uptake asymmetry. An overshoot of the brain extracellular fluid/plasma unbound concentration ratio at early time points was observed with bupropion; this was modeled as a time-dependent uptake clearance of the drug across the blood-brain barrier. Translation of the model was used to predict bupropion and hydroxybupropion exposure in human brain extracellular fluid after twice-daily administration of 150 mg bupropion. Predicted concentrations indicate that preferential inhibition of the dopamine and norepinephrine transporters by the metabolite, with little to no contribution by bupropion, would be expected at this therapeutic dose. Therefore, these results extend nuclear imaging studies on dopamine transporter occupancy and suggest that inhibition of both transporters contributes significantly to bupropion's therapeutic efficacy.

AB - Administration of bupropion [(6)-2-(tert-butylamino)-1-(3-chlorophenyl) propan-1-one] and its preformed active metabolite, hydroxybupropion [(6)-1-(3-chlorophenyl)-2-[(1-hydroxy-2-methyl-2-propanyl)amino]- 1-propanone], to rats with measurement of unbound concentrations by quantitative microdialysis sampling of plasma and brain extracellular fluid was used to develop a compartmental pharmacokinetics model to describe the blood-brain barrier transport of both substances. The population model revealed rapid equilibration of both entities across the blood-brain barrier, with resultant steadystate brain extracellular fluid/plasma unbound concentration ratio estimates of 1.9 and 1.7 for bupropion and hydroxybupropion, respectively, which is thus indicative of a net uptake asymmetry. An overshoot of the brain extracellular fluid/plasma unbound concentration ratio at early time points was observed with bupropion; this was modeled as a time-dependent uptake clearance of the drug across the blood-brain barrier. Translation of the model was used to predict bupropion and hydroxybupropion exposure in human brain extracellular fluid after twice-daily administration of 150 mg bupropion. Predicted concentrations indicate that preferential inhibition of the dopamine and norepinephrine transporters by the metabolite, with little to no contribution by bupropion, would be expected at this therapeutic dose. Therefore, these results extend nuclear imaging studies on dopamine transporter occupancy and suggest that inhibition of both transporters contributes significantly to bupropion's therapeutic efficacy.

UR - http://www.scopus.com/inward/record.url?scp=84963864559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963864559&partnerID=8YFLogxK

U2 - 10.1124/dmd.115.068932

DO - 10.1124/dmd.115.068932

M3 - Article

C2 - 26916207

AN - SCOPUS:84963864559

VL - 44

SP - 624

EP - 633

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 5

ER -